Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Tuebingen – page 28

607 clinical trials in Tuebingen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Tuebingen at a glance
607
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

607 trials in Tuebingen

Open in trial search

Schizophrenia

Not recruiting

Study on Long-Term Safety of Iclepertin for Patients with Schizophrenia Who Completed Previous Trials

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Iclepertin
  • Sponsor:Boehringer Ingelheim International GmbH

Systemic scleroderma

Not recruiting

Study of anifrolumab effectiveness compared to placebo in adults aged 18-70 with systemic sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Psoriatic arthropathy

Not recruiting

Study on Deucravacitinib and Apremilast for Patients with Active Psoriatic Arthritis New to Biologic Treatments or Previously on TNFα Inhibitors

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Pembrolizumab and Axitinib Combination Versus Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Merck Sharp & Dohme LLC

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Treating Moderate to Severe Plaque Psoriasis in Adults

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Jnj-77242113
  • Sponsor:Janssen Cilag International

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Obesity

Not recruiting

Study of KAI-9531 in Adults With Obesity or Overweight and Weight-Related Health Problems Without Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:HRS 9531

Efficacy and Safety Evaluation of Odevixibat in Pediatric Biliary Atresia Post-Kasai Hepatoportoenterostomy: A Double-Blind, Randomized, Placebo-Controlled Trial

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Tuebingen

What the registry says about research in the country

01 Autoimmune & Inflammatory Conditions

Innovative research focusing on cutaneous lupus erythematosus and psoriatic arthritis, evaluating novel therapeutic approaches for managing chronic inflammatory conditions.

  • Lupus skin manifestations
  • Joint inflammation
  • Autoimmune responses

Studies aim to assess new treatment options for improving patient outcomes and quality of life.

02 Oncology Research

Comprehensive studies on various cancer types, including metastatic prostate cancer and basal cell carcinoma, exploring innovative treatment combinations.

  • Advanced cancer therapies
  • Pediatric liver tumors
  • Targeted treatments

Research focuses on improving survival rates and developing more effective treatment strategies.

03 Neurological Disorders

Groundbreaking research in multiple system atrophy and seizure disorders, investigating new therapeutic approaches for complex neurological conditions.

  • Brain function disorders
  • Movement disorders
  • Epilepsy management

Clinical trials aim to enhance treatment options for patients with challenging neurological conditions.

04 Ophthalmology Studies

Advanced research in eye disorders, including Leber congenital amaurosis and geographic atrophy, focusing on innovative treatment approaches.

  • Retinal diseases
  • Visual function
  • Gene therapy

Trials aim to preserve and improve vision in patients with rare and progressive eye conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.